About Palvella Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://palvellatx.com/
Frequently Asked Questions
What is the 52-week range for PVLA?
The 52-week high is $161.38 and the 52-week low is $60.49.
What is the P/E ratio for PVLA?
The P/E ratio data is currently unavailable.
What is the dividend yield for PVLA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -47.84%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -39.71%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 44.27.
Analyst Recommendation Trends
Wall Street analyst consensus for PVLA over the last few months:
Latest PVLA News
Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger
Palvella Therapeutics advances QTORIN rapamycin for microcystic lymphatic malformations with strong Phase 3 data. Read more on PVLA stock here.
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric and adult patients living with microcystic lymphatic malformations in the U.S. WAYNE, Pa., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a cli
Palvella Therapeutics Receives Third Year Of Grant Funding From FDA Office Of Orphan Products Development For Phase 3 SELVA Trial And Ongoing Open-Label Extension Study Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic Malformations
The award follows FDA review of Palvella’s annual performance progress report, which included results from the Phase 3 SELVA trial. In February 2026, Palvella announced positive topline results from the Phase 3 SELVA
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer
Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas Leader in pediatric dermatology with nearly 20 years of distinguished clinical, research, and academic experience Longstanding Palvella clinical collaborator and QTORIN™ trial investigator brings deep understanding of the unmet needs in serious, rare skin diseases including vascular anomalies Dr. Treat to lead medical strategy as Palvella moves QTORIN™ rapamyci
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-16 | Goin Kathleen | -2,148 | - | - |
| 2026-09-16 | Goin Kathleen | -2,154 | - | - |
| 2026-09-16 | Goin Kathleen | -1,654 | $153.2434 | $253,465 |
| 2026-09-16 | Goin Kathleen | -989 | $152.3617 | $150,686 |
| 2026-09-16 | Goin Kathleen | -1,659 | $151.1589 | $250,773 |
| 2026-09-16 | Goin Kathleen | +2,148 | $9.08 | $19,504 |
| 2026-09-16 | Goin Kathleen | +2,154 | $7.14 | $15,380 |
| 2026-09-15 | JENKINS GEORGE M | -560 | $151.3263 | $84,743 |
| 2026-09-15 | JENKINS GEORGE M | -263 | $150.4045 | $39,556 |
| 2026-09-15 | JENKINS GEORGE M | -954 | $149.3779 | $142,507 |
| 2026-09-14 | JENKINS GEORGE M | -1,560 | $153.099 | $238,834 |
| 2026-09-14 | JENKINS GEORGE M | -6,160 | $152.1159 | $937,034 |
| 2026-09-14 | JENKINS GEORGE M | -5,632 | $151.4625 | $853,037 |
| 2026-09-11 | JENKINS GEORGE M | -1,274 | $153.0591 | $194,997 |
| 2026-09-11 | JENKINS GEORGE M | -4,577 | $151.7157 | $694,403 |
| 2026-09-11 | JENKINS GEORGE M | -6,520 | $150.6189 | $982,035 |
| 2026-09-02 | KIRITSY CHRISTOPHER P | -313 | - | - |
| 2026-09-02 | KIRITSY CHRISTOPHER P | -313 | $157 | $49,141 |
| 2026-09-02 | KIRITSY CHRISTOPHER P | +313 | $127.2 | $39,814 |
| 2026-08-19 | Goin Kathleen | -2,148 | - | - |
| 2026-08-19 | Goin Kathleen | -2,154 | - | - |
| 2026-08-19 | Goin Kathleen | -302 | $156.77 | $47,345 |
| 2026-08-19 | Goin Kathleen | -102 | $155.5898 | $15,870 |
| 2026-08-19 | Goin Kathleen | -400 | $152.9975 | $61,199 |
| 2026-08-19 | Goin Kathleen | -1,998 | $151.7979 | $303,292 |
| 2026-08-19 | Goin Kathleen | -1,500 | $151.39 | $227,085 |
| 2026-08-19 | Goin Kathleen | +2,148 | $9.08 | $19,504 |
| 2026-08-19 | Goin Kathleen | +2,154 | $7.14 | $15,380 |
| 2026-07-15 | Goin Kathleen | -2,148 | - | - |
| 2026-07-15 | Goin Kathleen | -2,154 | - | - |
| 2026-07-15 | Goin Kathleen | -1,911 | $150.2529 | $287,133 |
| 2026-07-15 | Goin Kathleen | -1,029 | $149.2667 | $153,595 |
| 2026-07-15 | Goin Kathleen | -840 | $148.4018 | $124,658 |
| 2026-07-15 | Goin Kathleen | -522 | $147.1365 | $76,805 |
| 2026-07-15 | Goin Kathleen | +2,148 | $9.08 | $19,504 |
| 2026-07-15 | Goin Kathleen | +2,154 | $7.14 | $15,380 |
| 2026-06-29 | Pauls Matthew | +6,000 | - | - |
| 2026-06-17 | Goin Kathleen | -2,148 | - | - |
| 2026-06-17 | Goin Kathleen | -2,154 | - | - |
| 2026-06-17 | Goin Kathleen | -25 | $112.23 | $2,806 |
| 2026-06-17 | Goin Kathleen | -1,887 | $111.3128 | $210,047 |
| 2026-06-17 | Goin Kathleen | -2,390 | $110.2594 | $263,520 |
| 2026-06-17 | Goin Kathleen | +2,148 | $9.08 | $19,504 |
| 2026-06-17 | Goin Kathleen | +2,154 | $7.14 | $15,380 |
| 2026-06-12 | Korenberg Matthew E | -1,000 | - | - |
| 2026-06-12 | Korenberg Matthew E | +1,000 | $13.6 | $13,600 |
| 2026-06-10 | Doux John | +3,000 | - | - |
| 2026-06-10 | Wessel Tadd S. | +3,000 | - | - |
| 2026-06-10 | Davis Todd C | +3,000 | - | - |
| 2026-06-10 | JENKINS GEORGE M | +3,000 | - | - |
| 2026-06-10 | KIRITSY CHRISTOPHER P | +3,000 | - | - |
| 2026-06-10 | HERON ELAINE J | +3,000 | - | - |
| 2026-05-20 | Goin Kathleen | -2,148 | - | - |
| 2026-05-20 | Goin Kathleen | -2,154 | - | - |
| 2026-05-20 | Goin Kathleen | -48 | $111.895 | $5,371 |
| 2026-05-20 | Goin Kathleen | -891 | $111.2963 | $99,165 |
| 2026-05-20 | Goin Kathleen | -3,363 | $110.3464 | $371,095 |
| 2026-05-20 | Goin Kathleen | +2,148 | $9.08 | $19,504 |
| 2026-05-20 | Goin Kathleen | +2,154 | $7.14 | $15,380 |
| 2026-04-15 | Goin Kathleen | -2,148 | - | - |
| 2026-04-15 | Goin Kathleen | -2,154 | - | - |
| 2026-04-15 | Goin Kathleen | -100 | $130.33 | $13,033 |
| 2026-04-15 | Goin Kathleen | -639 | $129.1692 | $82,539 |
| 2026-04-15 | Goin Kathleen | -561 | $128.2349 | $71,940 |
| 2026-04-15 | Goin Kathleen | -1,500 | $127.1254 | $190,688 |
| 2026-04-15 | Goin Kathleen | -1,502 | $125.9647 | $189,199 |
| 2026-04-15 | Goin Kathleen | +2,148 | $9.08 | $19,504 |
| 2026-04-15 | Goin Kathleen | +2,154 | $7.14 | $15,380 |
| 2026-04-13 | Doux John | +6,000 | - | - |
| 2026-03-30 | JENKINS GEORGE M | +445 | $112.3 | $49,974 |
| 2026-03-18 | Goin Kathleen | -2,148 | - | - |
| 2026-03-18 | Goin Kathleen | -2,154 | - | - |
| 2026-03-18 | Goin Kathleen | -304 | $119.0817 | $36,201 |
| 2026-03-18 | Goin Kathleen | -1,730 | $118.3681 | $204,777 |
| 2026-03-18 | Goin Kathleen | -2,268 | $117.5632 | $266,633 |
| 2026-03-18 | Goin Kathleen | +2,148 | $9.08 | $19,504 |
| 2026-03-18 | Goin Kathleen | +2,154 | $7.14 | $15,380 |
| 2026-02-27 | JENKINS GEORGE M | +4,000 | $125 | $500,000 |
| 2026-02-27 | HERON ELAINE J | +2,400 | $125 | $300,000 |
| 2026-02-18 | Goin Kathleen | -2,148 | - | - |
| 2026-02-18 | Goin Kathleen | -2,154 | - | - |
| 2026-02-18 | Goin Kathleen | -1,276 | $79.9651 | $102,035 |
| 2026-02-18 | Goin Kathleen | -3,026 | $79.1569 | $239,529 |
| 2026-02-18 | Goin Kathleen | +2,148 | $9.08 | $19,504 |
| 2026-02-18 | Goin Kathleen | +2,154 | $7.14 | $15,380 |
| 2026-02-05 | Martini Jeffrey S | +64,318 | - | - |
| 2026-02-05 | Kline Ashley Hartmann | +38,517 | - | - |
| 2026-02-05 | Kaupinen Wes | +124,603 | - | - |
| 2026-02-05 | Korenberg Matthew E | +44,123 | - | - |
| 2026-02-05 | Goin Kathleen | +48,956 | - | - |
| 2026-01-21 | Goin Kathleen | -2,148 | - | - |
| 2026-01-21 | Goin Kathleen | -2,154 | - | - |
| 2026-01-21 | Goin Kathleen | -3,749 | $97.94 | $367,177 |
| 2026-01-21 | Goin Kathleen | -553 | $95.49 | $52,806 |
| 2026-01-21 | Goin Kathleen | +2,148 | $9.08 | $19,504 |
| 2026-01-21 | Goin Kathleen | +2,154 | $7.14 | $15,380 |
| 2025-12-17 | Goin Kathleen | -2,148 | - | - |
| 2025-12-17 | Goin Kathleen | -2,154 | - | - |
| 2025-12-17 | Goin Kathleen | -4,302 | $96.472 | $415,023 |
| 2025-12-17 | Goin Kathleen | +2,148 | $9.08 | $19,504 |
| 2025-12-17 | Goin Kathleen | +2,154 | $7.14 | $15,380 |
| 2025-11-19 | Goin Kathleen | -2,148 | - | - |
| 2025-11-19 | Goin Kathleen | -2,154 | - | - |
| 2025-11-19 | Goin Kathleen | -2,802 | $86.5053 | $242,388 |
| 2025-11-19 | Goin Kathleen | -1,500 | $85.7183 | $128,577 |
| 2025-11-19 | Goin Kathleen | +2,148 | $9.08 | $19,504 |
| 2025-11-19 | Goin Kathleen | +2,154 | $7.14 | $15,380 |